Hayden E. Klein

Research found that ibrutinib reduces red blood cell aggregation in patients with chronic lymphocytic leukemia (CLL), while obinutuzumab/venetoclax does not significantly alter blood viscosity.

According to research, PSAT1, PSRC1, COLEC12, HP, and PLLP may play a role in small cell lung cancer metabolism, immune response, and tumor progression, though more research is needed.

According to a review of hospital-based cross-sectional studies, almost half the type 2 diabetes population is micronutrient deficient.

The pause has raised concerns among health officials and state leaders, as the vague wording leaves billions in Medicaid funding at risk, potentially disrupting coverage for millions of Americans.

Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address small cell lung cancer's aggressive nature and resistance to conventional therapy.

Alcohol consumption can elevate cancer risk through mechanisms such as DNA damage, hormonal changes, and oxidative stress, with risks increasing alongside consumption levels.

Trilaciclib significantly reduced chemotherapy-induced myelosuppression in extensive-stage small cell lung cancer, which authors say minimizes the need for supportive care.

Patients with visual impairments face major physical and financial barriers when seeking emergency care.

Cemiplimab significantly reduced the risk of recurrence or death in patients with high-risk cutaneous squamous cell carcinoma (CSCC) post-surgery.

Small cell lung cancer (SCLC) is strongly linked to smoking, with about 80% of lung cancer deaths attributed to tobacco use.

However, metformin did not protect Black patients against squamous cell carcinoma specifically.

The Commission proposed using new measures beyond body mass index (BMI) to define when obesity is a disease.

A report from the Federal Trade Commission (FTC) has determined that pharmacy benefit managers (PBMs) are linked to significant cost increases for cancer, HIV, and other critical specialty drugs.

Latine individuals in the US face higher morbidity and mortality in skin cancer outcomes despite lower lifetime risk.

An Institute for Value-Based Medicine regional event in Houston, Texas, covered inconsistencies with the integration of precision medicine in oncology practices, the evolution of treatment for multiple myeloma, and more.

According to Ian Neeland, MD, strategies like pharmacist-led counseling, patient education programs, and patient assistance initiatives are key to addressing therapeutic inertia.

From drug shortages to the approval of a nasal spray flu vaccine, the top population health stories explored critical challenges and advancements impacting the US health care landscape.

The top content from the Institute for Value-Based Medicine® (IVBM®) highlighted innovative approaches to improving care delivery, addressing obesity, and tackling health inequities across various disciplines.

Some of the top heart failure research looked at statins and semaglutide for heart failure with preserved ejection fraction, diabetes-related heart failure risks, and the protective cardiovascular effects of COVID-19 vaccination.

An analysis revealed global trends and emerging focus areas in Duchenne muscular dystrophy (DMD) research, emphasizing the growing impact of precision medicine and gene therapies.

The FDA issued a complete response letter for sotagliflozin (Zynquista) as an adjunct to insulin therapy for glycemic control.

Ian Neeland, MD, discusses the CINEMA program's impact on addressing social determinants of health (SDOH) in Ohio and the importance of precision risk tests to reduce cardiovascular metabolic disease risk.

Septal circumferential strain (Ecc) was significantly decreased in LGE-negative boys with Duchenne muscular dystrophy (DMD) and correlated to ventricle changes.

The CONNECT2-EDO51 phase 2 trial looks at PGN-EDO51, an investigational therapy for Duchenne muscular dystrophy (DMD), and is still ongoing in the United Kingdom.

Hans Lee, MD, explores how minimal residual disease (MRD) testing guides treatment decisions for multiple myeloma and highlights the value of patient preferences.

From imaging innovations to new treatment approvals, 2024 brought advancements in Duchenne muscular dystrophy care and research.

Subcutaneous amivantamab joins a growing list of drugs receiving complete response letters due to manufacturing facility issues.

Adolescent substance use remains at record lows in 2024, extending declines first observed during the COVID-19 pandemic.

Health care conferences this year showcased advancements in treatments for chronic obstructive pulmonary disease and sleep apnea, discussions around health policy and economic research, and more.

Ellen Francis, PhD, discusses the benefits, challenges, and future implications of implementing earlier diabetes screening for pregnant women.